Dive into the latest fiscal year with Xeris Biopharma's annual report, a comprehensive chronicle of our progress, milestones, and mission to transform lives through innovative, ready-to-use, liquid medicine. As we wind down 2021, our commitment to enhancing patients' access to critical medicines remains unyielding.

The annual report is not just a financial overview; it's a testament to our dedication to improving healthcare and a roadmap for our future. Let's delve into the happenings of 2021, our strategic initiatives, and the upcoming years.

Financial Milestones and Growth
Fiscal 2021 brought significant financial milestones, reflecting our expanding scope and reach. We witnessed a 36% increase in total revenue, driven largely by the success of our lead product, Gvoke, and strategic partnerships.

Our research and development expenses also surged, reflecting our commitment to advancing our pipeline. This increase aligns with our long-term vision to diversify our portfolio and broaden our therapeutic focus.
Commercial Excellence

Our commercial strategies yielded commendable results, with Gvoke's market penetration expanding significantly. Thanks to our reimbursement strategies and market access efforts, more patients than ever before have access to our lifesaving medicine.
Our expansion into new markets, namely diabetes specialty pharmacies, further bolstered our reach. Initiatives like our 'Access for All' program underscored our commitment to ensuring affordability for uninsured and underinsured patients.
.Product Pipeline Progress

Our late-stage pipeline flourished in 2021. We advanced[X] through two Phase 3 clinical trials, bringing us closer to potential new treatments for critical conditions. We also expandedinto new indications for Gvoke, further demonstrating the versatility of our platform.
Additionally, our earlier-stage pipeline made significant strides. We initiated Phase 2 trials for[Y] and [Z], and pre-clinical programs like[W] showed promising results, contributing to our robust pipeline.
Partnerships and Collaborations

Strategic collaborations and partnerships lie at the heart of our success. In 2021, we inked a strategic agreement with a leading pharmaceutical company to expedite the development and commercialization of our ready-to-use liquid products.
We also bolstered our presence in the rare disease space through a collaboration with a preeminent advocacy organization. Together, we aim to improve access to care and treatments for patients with rare diseases.




















Investing in Our Future
We expanded our workforce, welcoming talented individuals who share our passion for transforming medicine. We also invested in our infrastructure, moving into a new, state-of-the-art facility to support our growing operations.
Moreover, we fortified our balance sheet with a successful public offering, ensuring we have the financial resources to execute our growth strategy and advance our pipeline.
As we turn our gaze to 2022, we look forward to building on our momentum. The road ahead holds promising milestones, including regulatory submissions, product launches, and further pipeline advancements. Stay tuned for more updates from Xeris Biopharma.